Business Context and Reporting Period
Company: American Shared Hospital Services
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 1995
Business Overview: The Company provides medical services including Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Nuclear Medicine, Ultrasound, Respiratory Therapy, and Gamma Knife services. As of May 10, 1995, there were 2,867,401 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 1995 | Q1 1994 | Dec 31, 1994 (Balance Sheet) |
|---|---|---|---|
| Revenues (Medical Services) | $8,672,000 | $9,873,000 | - |
| Total Costs & Expenses | $10,058,000 | $11,614,000 | - |
| Net Loss | ($1,283,000) | ($1,631,000) | - |
| Net Loss Per Share | ($0.45) | ($0.57) | - |
| Cash & Equivalents | $742,000 | $1,488,000 | $1,225,000 |
| Net Cash from Operations | $1,801,000 | $1,468,000 | - |
| Total Assets | $40,612,000 | - | $44,339,000 |
| Total Liabilities | $64,236,000 | - | $66,680,000 |
| Accumulated Deficit | ($33,182,000) | - | ($31,899,000) |
| Accrued Interest (Liability) | $9,027,000 | - | $8,497,000 |
Material Changes vs. Prior Period
- Revenue Decline: Medical services revenue decreased by $1,201,000 (12.2%) year-over-year. This was driven by a $1,407,000 drop in Respiratory Therapy revenues following the sale of department contracts in late 1994, and decreases in CT and Ultrasound revenues.
- Revenue Growth Areas: MRI revenues increased by $691,000 due to new contracts and higher utilization. Gamma Knife revenues rose by $95,000.
- Cost Reductions: Total costs of operations decreased by $1,651,000. Payroll costs dropped $959,000 primarily due to the Respiratory Therapy divestiture. Equipment rental expenses fell $787,000 following a lease restructuring.
- Increased Interest Expense: Interest expense rose $187,000 to $1,750,000 due to the reclassification of equipment leases from rentals to capitalized leases, increasing recorded interest.
- Improved Net Loss: Despite lower revenues, the net loss narrowed by $348,000 to $1,283,000, reflecting significant cost-cutting measures.
Outlook, Risks, and Contingencies
- Debt Default Status: The Company is in default on its Senior Subordinated Notes (16-1/2% and 14-3/4% due 1996) having suspended interest payments since October 1992. Accrued unpaid interest totaled approximately $9,046,000 as of April 15, 1995. Holders have the right to demand immediate repayment, which could force bankruptcy.
- Restructuring Agreement: On May 5, 1995, the Company entered a revised agreement with holders of ~96% of its Senior Subordinated Notes to repurchase them for cash and equity. The deal involves approximately $3.9 million in cash and issuance of 819,000 shares plus warrants. Closing is scheduled for May 17, 1995, subject to funding of $8 million in new credit facilities.
- Liquidity Concerns: Cash and cash equivalents declined to $742,000. The Company faces uncertainty over the next 12 months unless revenues increase and costs are further reduced. The proposed restructuring aims to save approximately $2.89 million annually in interest.
- Shareholder Dilution: The restructuring and new credit facility guarantees will significantly alter ownership. Existing shareholders (excluding the CEO) may own approximately 30% of the company post-restructuring, while the CEO (Dr. Bates) is expected to hold approximately 43%.
Investor Verification Checklist
- Closing of Restructuring: Verify if the May 17, 1995 closing of the debt repurchase and new credit facilities occurred as scheduled.
- Bankruptcy Risk: Confirm whether note holders have exercised their right to accelerate debt repayment given the default status.
- Revenue Sustainability: Assess if the growth in MRI and Gamma Knife revenues is sufficient to offset the permanent loss of Respiratory Therapy revenue.
- Ownership Structure: Review the final capitalization table to confirm the dilution of existing shareholders and the new ownership percentages of Dr. Bates and the note holders.
- Working Capital: Monitor cash flow to ensure the $742,000 cash balance is sufficient to meet ongoing operational obligations pending the new credit facility funding.